Lisa O’Rourke

3.9k citations

30 papers · 1.5k indexed · 1 hit paper · h-index 12

Oncology top 2%
Pulmonary and Respiratory Medicine top 5%
Molecular Biology
Cancer Research top 10%
Radiology, Nuclear Medicine and Imaging top 5%

Co-authors: Stephen Johnston J. Maltzman Peter R. Shepherd Allison Florance Michael F. Press John Pippen Xavier Pivot Mark D. Pegram
Topics: Advanced Breast Cancer Therapies (18 papers)Cancer Treatment and Pharmacology (16 papers)HER2/EGFR in Cancer Research (15 papers)
Cited by: Oncology Cancer Research Gastroenterology
Journals: Journal of Biological Chemistry Journal of Clinical Oncology Cancer Research
Partner nations: United Kingdom United States Spain

In The Last Decade

Lisa O’Rourke

30 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

2009 766 citations Stephen Johnston, John Pippen et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Lisa O’Rourke

Since Specialization

Citations

This map shows the geographic impact of Lisa O’Rourke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa O’Rourke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa O’Rourke more than expected).

Fields of papers citing papers by Lisa O’Rourke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa O’Rourke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa O’Rourke. The network helps show where Lisa O’Rourke may publish in the future.

Co-authorship network of co-authors of Lisa O’Rourke

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa O’Rourke. A scholar is included among the top collaborators of Lisa O’Rourke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa O’Rourke. Lisa O’Rourke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Nursing Considerations for the Clinical Management of Adverse Events Associated with Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma 2024 ·Seminars in Oncology Nursing ·(unknown),(unknown),(unknown),(unknown),(unknown),Stephanie Rogers,(unknown),Lisa O’Rourke,Kathleen Gray,Jaszianne Tolbert,Thomas Renaud,Saurabh Patel,(unknown),(unknown)	3
2	Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies 2019 ·Haematologica ·María‐Victoria Mateos,Andrew Spencer,Ajay K. Nooka,Luděk Pour,Katja Weisel,Michèle Cavo,Jacob P. Laubach,Gordon Cook,Shinsuke Iida,Lotfi Benboubker,Saad Z. Usmani,Sung‐Soo Yoon,Nizar J. Bahlis,Christopher Chiu,Jon Ukropec,Jordan M. Schecter,Xiang Qin,Lisa O’Rourke,Meletios Α. Dimopoulos	43
3	DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VS LENALIDOMIDE AND DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): EFFICACY AND SAFETY UPDATE (POLLUX) 2017 ·Hematological Oncology ·Nizar J. Bahlis,Philippe Moreau,Hareth Nahi,Torben Plesner,Hartmut Goldschmidt,Kenshi Suzuki,Robert Z. Orlowski,Neil Rabin,Merav Leiba,Albert Oriol,Ajai Chari,Jesús F. San Miguel,Paul G. Richardson,Sharjeel Usmani,Lisa O’Rourke,Kang Wu,Tineke Casneuf,Christopher Chiu,Xiang Qin,Meletios Α. Dimopoulos	3
4	Daratumumab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (POLLUX). 2017 ·Journal of Clinical Oncology ·Nizar J. Bahlis,Philippe Moreau,Hareth Nahi,Torben Plesner,Hartmut Goldschmidt,Kenshi Suzuki,Robert Z. Orlowski,Neil Rabin,Merav Leiba,Albert Oriol,Ajai Chari,Jesús F. San Miguel,Paul G. Richardson,Saad Z. Usmani,Lisa O’Rourke,Kaida Wu,Tineke Casneuf,Christopher Chiu,Xiang Qin,Meletios Α. Dimopoulos	6
5	Quantitative ER and PgR Assessment as Predictors of Benefit from Lapatinib in Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer 2013 ·Clinical Cancer Research ·Richard S. Finn,Michael F. Press,Judy Dering,Lisa O’Rourke,Allison Florance,Catherine Ellis,Anne‐Marie Martin,Stephen Johnston	20
6	The Acid Pocket: A Target for Treatment in Reflux Disease? 2013 ·The American Journal of Gastroenterology ·Peter J. Kahrilas,Kenneth E.L. McColl,Mark Fox,Lisa O’Rourke,Daniel Sifrim,A. J. P. M. Smout,Guy E. Boeckxstaens	110
7	Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib 2011 ·Current Medical Research and Opinion ·Beth Sherrill,Bintu Sherif,Mayur M. Amonkar,J. Maltzman,Lisa O’Rourke,Stephen Johnston	7
8	S1-4: Retrospective Analysis of Study EGF30008 by Mass-Spectrometry Based Serum Assay (VeriStrat®). 2011 ·Cancer Research ·Joanna Roder,Heinrich Röder,(unknown),Julia Grigorieva,Catherine Ellis,Allison Florance,(unknown),Lisa O’Rourke,S. Johnston	2
9	Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor–Positive Metastatic Breast Cancer 2010 ·The Oncologist ·Lee S. Schwartzberg,Sandra Franco,Allison Florance,Lisa O’Rourke,J. Maltzman,Stephen Johnston	158
10	Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor–Positive Metastatic Breast Cancer 2010 ·The Oncologist ·(unknown),Sandra Franco,Allison Florance,Lisa O’Rourke,J. Maltzman,Stephen Johnston	13
11	Quality of Life in Hormone Receptor–Positive HER-2+ Metastatic Breast Cancer Patients During Treatment with Letrozole Alone or in Combination with Lapatinib 2010 ·The Oncologist ·Beth Sherrill,Mayur M. Amonkar,Bintu Sherif,J. Maltzman,Lisa O’Rourke,Stephen Johnston	24
12	Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancerbreakdown → 2009 ·Journal of Clinical Oncology ·Stephen Johnston,John Pippen,Xavier Pivot,Mikhail Lichinitser,Saeed Sadeghi,Véronique Dièras,Henry Gómez,Gilles Romieu,Alexey Manikhas,Esther M. John,Michael F. Press,J. Maltzman,Allison Florance,Lisa O’Rourke,Cristina Oliva,Steven Stein,Mark D. Pegram	766
13	Decrease in serum extracellular domain of HER2 at 4 and 8 weeks is associated with prolonged progression-free survival on lapatinib monotherapy. 2009 ·Cancer Research ·Allan Lipton,Kim Leitzel,(unknown),(unknown),(unknown),Lisa O’Rourke,Anne Marie Martin,J. Maltzman	4
14	Correlation of tumor burden, liver and bone metastasis with serum extracellular domain HER2 expression in front-line metastatic breast cancer. 2009 ·Cancer Research ·S. Johnston,Lisa O’Rourke,(unknown),Mark D. Pegram,MF Press,J. Maltzman	1
15	Lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor positive HER2+ metastatic breast cancer (MBC): A quality-of-life (QOL) analysis 2009 ·Journal of Clinical Oncology ·Bintu Sherif,Beth Sherrill,Mayur M. Amonkar,Yun Wu,J. Maltzman,Lisa O’Rourke,Stephen Johnston	6
16	5077 Lapatinib plus letrozole vs. letrozole alone in patients (pts) with endocrine sensitive, HER2+, previously untreated metastatic breast cancer (MBC) with multiple (>3sites) or liver metastases 2009 ·European Journal of Cancer Supplements ·Xavier Pivot,J. Maltzman,Lisa O’Rourke,Allison Florance,S. Johnston	1
17	Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 Trial. 2009 ·Cancer Research ·Stephen Johnston,Mark D. Pegram,Michael F. Press,John Pippen,Xavier Pivot,Henry Gómez,Allison Florance,Lisa O’Rourke,J. Maltzman	49
18	TNF-α and leptin activate the α-isoform of class II phosphoinositide 3-kinase 2003 ·Biochemical and Biophysical Research Communications ·(unknown),Peter R. Shepherd,Lisa O’Rourke	25
19	Glucose-dependent Regulation of Cholesterol Ester Metabolism in Macrophages by Insulin and Leptin 2002 ·Journal of Biological Chemistry ·Lisa O’Rourke,Line M. Grønning,Stephen J. Yeaman,Peter R. Shepherd	90
20	Insulin and Leptin Acutely Regulate Cholesterol Ester Metabolism in Macrophages by Novel Signaling Pathways 2001 ·Diabetes ·Lisa O’Rourke,(unknown),Peter R. Shepherd	78

About Lisa O’Rourke

Lisa O’Rourke is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Endocrine and Autonomic Systems, having authored 30 papers that have together received 1.5k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (18 papers), Cancer Treatment and Pharmacology (16 papers) and HER2/EGFR in Cancer Research (15 papers). The work is most often cited by research in Oncology (984 citations), Cancer Research (291 citations) and Gastroenterology (103 citations). Lisa O’Rourke has collaborated with scholars based in United Kingdom, United States and Spain. Frequent co-authors include Stephen Johnston, J. Maltzman, Peter R. Shepherd, Allison Florance, Michael F. Press, John Pippen, Xavier Pivot, Mark D. Pegram, Henry Gómez and Alexey Manikhas. Their work appears in journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact